

LyFE Forum of Excellence 2022: What's new in lymphoid neoplasias?

Bellinzona, 4-6 February 2022 – **DRAFT** -

DAY 1 - FRIDAY, 04.02.2022

<i>Chairperson F. Cavalli</i>		
10:30-11:30	The provisional lymphoma entities in the WHO classification	L. Mazzucchelli
11:30-12:00	How many molecular types of DLBCL?	A. Tzankov
12:00-12:30	PET metrics replacing visual analysis in NHL?	L. Ceriani
12:30-13:30	Lunch	
<i>Chairperson E. Zucca</i>		
13:30-14:30	Tumor board: Difficult diagnoses	A. Moccia / L. Mazzucchelli
14:30-15:00	What's new as regards pathology in T cell lymphomas?	L. De Leval
15:00-15:30	What's new clinically in non cutaneous T cell lymphomas?	S. Luminari
15:30-15:50	Break	
15:50-16:30	The epigenetic regulation of the germinal center: Implications for lymphoma pathogenesis, immune evasion and treatment	L. Pasqualucci
16:30-17:00	Cutaneous T-cell lymphomas	H. Beltraminelli
17:00-18:00	Discussion of cases of participants	

DAY 2 - SATURDAY, 05.02.2022

<i>Chairperson A. Moccia</i>		
08:30-09:15	Hodgkin lymphomas: soon 100% cured	P. Johnson
09:15-09:35	What's new in PMBCL?	E. Zucca
09:35-10:00	What's new in follicular lymphomas?	F. Cavalli
10:00-10:30	What's new in marginal zone lymphomas?	D. Rossi
10:30-11:00	Break	
11:00-12:00	Targeted therapies	
	- State of the art in NHL	A. Stathis
	- Mechanisms of resistance	F. Bertoni
	- The paradigm of CLL	D. Rossi
12:00-12:45	From chronic infection to genomic instability and B-cell lymphoma	D. Robbiani
12:45-14:00	Lunch	
<i>Chairperson D. Rossi</i>		
14:00-14:45	The standard therapy of DLBCL (including CNS prophylaxis)	A. Moccia
14:45-15:10	What's new in mantle cell lymphoma?	U. Novak
15:10-15:45	Break	
15:45-16:15	Burkitt and high grade lymphomas with and without myc and bcl2 rearrangements	S. Luminari
16:15-17:00	Immunotherapy in NHL: State of the art	U. Novak
17:00-18:00	Discussion of cases of participants	

DAY 3 - SUNDAY, 06.02.2022

<i>Chairperson F. Cavalli</i>		
09:00-10:00	Discussion of cases of participants	
10:00-10:40	Myeloma	E. Lerch
10:40-11:15	Amyloidosis and other gammopathies of clinical significance	B. Gerber
11:15-11:30	Concluding remarks & End of the meeting	F. Cavalli